M Ghavipour1, G Sotoudeh2, E Tavakoli3, K Mowla4, J Hasanzadeh5, Z Mazloom3. 1. Department of Community Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Science, Shiraz, Iran. 2. Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. 3. Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Science, Shiraz, Iran. 4. Department of Rheumatology, Ahwaz University of Medical Science, Ahwaz, Iran. 5. Department of Epidemiology, School of Health, Shiraz University of Medical Science, Shiraz, Iran.
Abstract
BACKGROUND/ OBJECTIVES: Since the main characteristics of Rheumatoid Arthritis (RA) are joint dysfunction caused by inflammation and serious pain, anti-inflammatory agents may alleviate the clinical symptoms in RA. Pomegranate juice is rich in polyphenolic compounds that possess antioxidant and anti-inflammatory activities. This study aimed to determine the beneficial effects of pomegranate extract (POMx) in RA patients. SUBJECTS/ METHODS: A total of 55 RA patients were enrolled and randomly allocated to an intervention group (n=30) or a control group (n=25). The intervention group received 2 capsules of 250 mg POMx and the control group 2 capsules of 250 mg cellulose per day for 8 weeks. At the beginning of the study and after 8 weeks, Health Assessment Questionnaire (HAQ) and Disease Activity Score (DAS) 28 were completed and serum concentrations of C-reactive protein (CRP), matrix metalloproteinases 3 (MMP3), malondialdehyde (MDA), glutathione peroxidase (GPx) and erythrocyte sedimentation rate (ESR) were analyzed using standard methods and compared between the two groups. RESULTS: Compared with the placebo group, POMx supplement significantly reduced the score of DAS28 (P<0.001) which could be related to the decrease in swollen (P<0.001) and tender joints (P=0.001) count, pain intensity (P=0.003) and ESR levels (P= 0.03). POMx consumption also decreased HAQ score (P=0.007) and morning stiffness (P=0.04) and increased GPx concentrations (P<0.001). There were no differences in the change in mean MMP3, CRP and MDA levels between two groups. CONCLUSIONS: POMx alleviates disease activity and improves some blood biomarkers of inflammation and oxidative stress in RA patients.
RCT Entities:
BACKGROUND/ OBJECTIVES: Since the main characteristics of Rheumatoid Arthritis (RA) are joint dysfunction caused by inflammation and serious pain, anti-inflammatory agents may alleviate the clinical symptoms in RA. Pomegranate juice is rich in polyphenolic compounds that possess antioxidant and anti-inflammatory activities. This study aimed to determine the beneficial effects of pomegranate extract (POMx) in RApatients. SUBJECTS/ METHODS: A total of 55 RApatients were enrolled and randomly allocated to an intervention group (n=30) or a control group (n=25). The intervention group received 2 capsules of 250 mg POMx and the control group 2 capsules of 250 mg cellulose per day for 8 weeks. At the beginning of the study and after 8 weeks, Health Assessment Questionnaire (HAQ) and Disease Activity Score (DAS) 28 were completed and serum concentrations of C-reactive protein (CRP), matrix metalloproteinases 3 (MMP3), malondialdehyde (MDA), glutathione peroxidase (GPx) and erythrocyte sedimentation rate (ESR) were analyzed using standard methods and compared between the two groups. RESULTS: Compared with the placebo group, POMx supplement significantly reduced the score of DAS28 (P<0.001) which could be related to the decrease in swollen (P<0.001) and tender joints (P=0.001) count, pain intensity (P=0.003) and ESR levels (P= 0.03). POMx consumption also decreased HAQ score (P=0.007) and morning stiffness (P=0.04) and increased GPx concentrations (P<0.001). There were no differences in the change in mean MMP3, CRP and MDA levels between two groups. CONCLUSIONS: POMx alleviates disease activity and improves some blood biomarkers of inflammation and oxidative stress in RApatients.
Authors: Mari C W Myhrstad; Harald Carlsen; Olov Nordström; Rune Blomhoff; Jan Øivind Moskaug Journal: Free Radic Biol Med Date: 2002-03-01 Impact factor: 7.376
Authors: E Stachowska; B Dolegowska; V Dziedziejko; M Rybicka; M Kaczmarczyk; J Bober; M Rac; B Machalinski; D Chlubek Journal: J Physiol Pharmacol Date: 2009-03 Impact factor: 3.011
Authors: Richard M van Vugt; Philip J Rijken; Anton G Rietveld; Arno C van Vugt; Ben A C Dijkmans Journal: Clin Rheumatol Date: 2008-02-15 Impact factor: 2.980
Authors: Yolima Puentes-Osorio; Pedro Amariles; Miguel Ángel Calleja; Vicente Merino; Juan Camilo Díaz-Coronado; Daniel Taborda Journal: Auto Immun Highlights Date: 2021-05-31
Authors: Anna K E Vadell; Linnea Bärebring; Erik Hulander; Inger Gjertsson; Helen M Lindqvist; Anna Winkvist Journal: Am J Clin Nutr Date: 2020-06-01 Impact factor: 7.045